EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitVideo/AudioLeitlinieOpen Access · CC BY-NC-ND 4.0

Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed‐ratio basal insulin glucagon‐like peptide‐1 receptor agonist combinations?

Kevin Cowart iD, Nicholas W Carris iD

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16502 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Kevin Cowart und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of South Florida, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Glycated Hemoglobin, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Basal insulin and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are available in two fixed‐ratio combinations (FRCs) for the treatment of type 2 diabetes (T2D), insulin degludec with liraglutide and insulin glargine with lixisenatide. FRCs offer a convenient strategy to administer basal insulin and a GLP‐1 RA, taking advantage of complementary mechanisms in a single injection to minimize treatment burden and improve glycemic control while mitigating weight gain. For most, a glycated haemoglobin (HbA1c) goal for patients with T2D using a FRC would be

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsGlycated HemoglobinHypoglycemic AgentsHumansBlood GlucoseDrug CombinationsDrug Therapy, CombinationGlycemic ControlInsulin GlargineInsulin, Long-ActingLiraglutidePeptidesPractice Guidelines as TopicGlucagon-Like Peptide-2 Receptor

Stichwörter der Autor:innen

GLP‐1 analoguebasal insulinglycaemic controltype 2 diabetes

Substanzen

Blood GlucoseDrug CombinationsGlucagon-Like Peptide-1 Receptor AgonistsGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic Agentsinsulin degludecInsulin GlargineInsulin, Long-ActingLiraglutide

Autor:innen und Institutionen

  • University of South Florida, Tampa, Florida, USA.

ORCID-Profile: Kevin Cowart, Nicholas W Carris

Zitieren

APA

Cowart, K., & Carris, N. W. (2025). Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed‐ratio basal insulin glucagon‐like peptide‐1 receptor agonist combinations?. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16502

Vancouver

Cowart K, Carris NW. Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed‐ratio basal insulin glucagon‐like peptide‐1 receptor agonist combinations?. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16502

BibTeX
@article{Cowart2025,
  author = {Cowart, Kevin and Carris, Nicholas W},
  title = {Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed‐ratio basal insulin glucagon‐like peptide‐1 receptor agonist combinations?},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16502}
}
Kostenlos starten →